Evaluation of the effectiveness of lipid-lowering agents by V. G. Shevko, M. A. Galas, T. L. Galankin, A. S. Kolbin

Subjects: Get full text

Surrogate endpoints in cost-effectiveness analysis for use in medical technology assessment by T. I. Busheva, A. R. Kasimova, A. S. Kolbin, A. N. Pshenichnikov

Subjects: Get full text

Surrogate endpoints for neonatal outcome: A rapid review by Shiraz El Adam, Karissa Johnston, Maanasa Venkataraman, Vanessa Perez Patel

Subjects: Get full text

Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis by L. Leung, J.M. Kirkwood, S. Srinivasan, M. Dyer, A. Qian, M.-M. Pourrahmat, E. Kasireddy, J.R. May, A. Moshyk, M. Kurt

Subjects: “…surrogate endpoints…”
Get full text

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas by Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim

Subjects: Get full text

Surrogate endpoints in diabetic kidney disease: current perspectives and future directions by Can Cao, Jiale Zhang, Tong Ma, Juan Miao, Weiwei Sun

Subjects: Get full text

Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis by Yubingxue Liu, Jianlin Long, Huan Deng, Wen Chen

Subjects: Get full text

Endpoints: types, selection, interpretation of the results obtained on the example of cardiology studies by A. R. Navasardyan, S. Yu. Martsevich

Subjects: Get full text

Facilities of diagnosis and monitoring of optic neuropathy in primary open-angle glaucoma. Part 1 by O. A. Kiseleva, N. V. Balatskaya, A. M. Bessmertny, V. I. Kotelin

Subjects: Get full text

Cancer Drugs Approved Based on Surrogate Endpoint: A Retrospective Observational Study in the United States and China by Ting Zhu, Jinjia Zhong, Yafang Huang

Subjects: Get full text

Tutorial on Conditional Simulations With a Tumor Size‐Overall Survival Model to Support Oncology Drug Development by Sebastiaan C. Goulooze, Morris Muliaditan, Richard C. Franzese, Alejandro Mantero, Sandra A. G. Visser, Murad Melhem, Teun M. Post, Chetan Rathi, Herbert Struemper

Subjects: Get full text

Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making by Herbert Struemper, Chetan Rathi, Morris Muliaditan, Sebastiaan C. Goulooze, Richard C. Franzese, Alejandro Mantero, Murad Melhem, Teun M. Post, Sandra A. G. Visser

Subjects: Get full text

Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the... by Jiacong Liu, Ziheng Wu, Shihong Zhou, Wang Lv, Yiqing Wang, Pinghui Xia, Linhai Zhu, Jian Hu

Subjects: Get full text

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs by Oriol Solà-Morales, Timm Volmer, Lorenzo Mantovani

Subjects: Get full text

The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs by Xi Yang, Yuanyuan Zhang, Shuangzheng Jia, Yong Yang, Jie Zhu, Wei Li, Lingying Wu, Jusheng An, Manni Huang

Subjects: Get full text

Blood biomarkers as surrogate endpoints in Alzheimer’s disease research by Guogen Shan, Hui Li, Yahui Zhang, Guoqiao Wang, Charles Bernick

Subjects: Get full text

Subsequent Survival and Loss of Lifetime for Patients With Progression‐Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population‐Based Analy... by Yang Liu, Yaqian Han, Mei Feng, Ye Zhang, Kai Wang, Yuan Qu, Xuesong Chen, Jianghu Zhang, Jingwei Luo, Runye Wu, Ye‐Xiong Li, Xiaodong Huang, Qiuyan Chen, Jingbo Wang, Junlin Yi

Subjects: Get full text

Selection of Endpoints for Clinical Studies of Ophthalmic Drugs by M. O. Komarova

Subjects: Get full text